Eli Lilly Outperforms as Novo Nordisk Sets Pill Launch

28 days ago

Christine Kino

"Well, we got to take a look at Eli Lily today given the Nova Nordisk news. So, Eli Liy shares uh ticker ly and those shares just up a touch right now at the moment... But overall, Eli Liy still very much winning uh that raise when it comes to at least share moves this year. They have risen uh 39% versus Novo's 47% decline. But yeah, I mean the Novo uh US ability uh presence shall we say is certainly potential threat to Eli Lilly here."

Christine Kino discusses the competitive dynamics between Eli Lilly and Novo Nordisk, noting that while Novo is launching an obesity pill in early January, Eli Lilly's shares have risen 39% compared to Novo's 47% decline, suggesting a stronger market performance currently.

Related Stocks